title: Risk factors for in utero or intrapartum mother-to-child transmission of human immunodeficiency virus type 1 in Thailand.
abstract: BACKGROUND
  The identification of risk factors for in utero and intrapartum transmission of human immunodeficiency virus type 1 (HIV-1) is crucial to the design and understanding of preventive interventions.
  
  
  METHODS
  The randomized Perinatal HIV Prevention Trial-1 enrolled 1437 pregnant women and their non-breast-fed infants, to compare the efficacy of various durations of zidovudine prophylaxis. Using univariate and multivariate logistic regression analyses, we studied the role that factors known or occurring at various times during gestation or delivery play in in utero and intrapartum transmission.
  
  
  RESULTS
  Variables independently associated with in utero transmission were HIV-1 load >35,000 copies/mL (adjusted odds ratio [AOR], 4.2) and delayed initiation of maternal zidovudine prophylaxis until >31.4 weeks gestation (AOR, 3.0). Variables associated with intrapartum transmission were HIV-1 load >10,000 copies/mL (AOR, 3.8 for 10,000-35,000 copies/mL and 7.1 for >35,000 copies/mL), induction of labor (AOR, 2.6), and premature labor with tocolysis (AOR, 15.1).
  
  
  CONCLUSIONS
  With the exception of very high HIV-1 load, risk factors for in utero transmission were different from those for intrapartum transmission. Optimal prophylactic interventions must address each of the major risk factors, with appropriate timing.
authors.affiliation: Institut de Recherche pour le Developpement, UMI 174 "Epidemiologie Clinique, Sante Maternelle et Infantile et Sida", Paris, France. gjourdai@hsph.harvard.edu
authors.forename: Gonzague
authors.initials: G
authors.lastname: Jourdain
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Mary
authors.forename: Sophie Le
authors.initials: SL
authors.lastname: Coeur
authors.forename: Nicole
authors.initials: N
authors.lastname: Ngo-Giang-Huong
authors.forename: Praparb
authors.initials: P
authors.lastname: Yuthavisuthi
authors.forename: Aram
authors.initials: A
authors.lastname: Limtrakul
authors.forename: Patrinee
authors.initials: P
authors.lastname: Traisathit
authors.forename: Kenneth
authors.initials: K
authors.lastname: McIntosh
authors.forename: Marc
authors.initials: M
authors.lastname: Lallemant
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D005260:Female; D005315:Fetal Diseases / Q000517:prevention & control* / Q000821:virology*; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission*; D015497:HIV-1; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D016015:Logistic Models; D008297:Male; D016017:Odds Ratio; D036801:Parturition; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000821:virology; D018570:Risk Assessment; D012307:Risk Factors; D013785:Thailand / Q000453:epidemiology; D016896:Treatment Outcome; D019562:Viral Load; D015215:Zidovudine / Q000627:therapeutic use*
chemical_list: D019380:Anti-HIV Agents; D015215:Zidovudine